INCIDENCE, INITIAL MANAGEMENT AND FOLLOW-UP
. Our endpoints were PPH and the requirement of secondary uterotonics. We developed a prediction model in the women treated with oxytocin using logistic regression. We then evaluated if the predicted risk could be used as a treatment selection marker.
Results: Within 1020 women treated with bolus oxytocin, risk indicators for PPH were parity, a previous CS, maternal anaemia and birthweight (area under the ROC-curve 0.75). The model could classify women in a risk group for PPH between 2.4% to as high as 18.9%. There was no interaction between the risk classification and the treatment effect (P-value 0.29).
Conclusions: In a large cohort of women undergoing CS, the occurrence of PPH could be predicted. However, we could not identify a group of women that would specifically benefit from carbetocin or bolus oxytocin. Background: Postpartum haemorrhage (PPH) is the leading direct cause of maternal death worldwide. Uterine atony is the most common cause of PPH, and pharmacological prophylaxis is
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